Hemopurifier for HIV
This article was originally published in The Gray Sheet
Executive Summary
Aethlon Medical will begin a first-in-man study in September of its Hemopurifier extracorporeal blood filtration device for treating HIV, the firm says June 24. The study, which will be conducted in Punjab, India, follows two earlier Indian studies of the device's safety in other patients (1"The Gray Sheet" Sept. 4, 2006, p. 14). International regulatory efforts are focused on chronic infectious disease, including HIV and hepatitis C, and pandemic threats, such as avian flu and dengue hemorrhagic fever, while in the U.S., Aethlon has submitted an investigational device application to FDA to use Hemopurifier as a countermeasure against category "A" bioterror threats, which include smallpox and Ebola